aflibercept vs latanoprost
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of aflibercept and latanoprost. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Eylea
Xalatan
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Latanoprost eye drops help lower pressure inside your eye. It is used if you have open-angle glaucoma or ocular hypertension.
AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.
Latanoprost eye drops are used to lower high pressure in your eyes. This medicine is for people who have open-angle glaucoma or ocular hypertension. These conditions can damage your optic nerve and cause vision loss.
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
Latanoprost is like a natural substance in your body. It works by helping fluid drain better from inside your eye. This lowers the pressure in your eye.
- • Bleeding in the eye
- • Eye pain
- • Clouding of the lens of the eye (cataract)
- • Separation of the vitreous gel from the retina
- • Spots in your vision
- • Blurred vision
- • Burning or stinging
- • Redness of the eye
- • Feeling like something is in your eye
- • Itching
- Death 7,853
- Visual Impairment 2,013
- Blindness 1,459
- Endophthalmitis 1,372
- Visual Acuity Reduced 1,244
- Treatment Failure 5,915
- Fatigue 2,228
- Eye Irritation 2,189
- Intraocular Pressure Increased 1,768
- Headache 1,737
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Latanoprost can cause your iris (the colored part of your eye), eyelid, and eyelashes to get darker. The iris color change may be permanent. Eyelash changes, like increased length and thickness, are usually reversible when you stop using the medicine. Use with caution if you have a history of eye inflammation or herpes keratitis.
It is not known if AHZANTIVE can harm an unborn baby. AHZANTIVE should be used during pregnancy only if the benefit justifies the risk. It is also not known if AHZANTIVE passes into breast milk.
It is not known if latanoprost is safe to use during pregnancy. Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Also Compare, Nearby Drugs
Compare aflibercept with
Compare latanoprost with
How to Read This aflibercept vs latanoprost Comparison
aflibercept is classified in the Anti-VEGF (Ophthalmic Injection) drug class, while latanoprost sits within the Prostaglandin Analog (Ophthalmic) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aflibercept has 13,941 submissions while latanoprost has 13,837. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aflibercept or latanoprost.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.